Edition:
United Kingdom

Akers Biosciences Inc (AKER.OQ)

AKER.OQ on NASDAQ Stock Exchange Capital Market

0.25USD
18 Sep 2018
Change (% chg)

$-0.00 (-0.59%)
Prev Close
$0.26
Open
$0.25
Day's High
$0.26
Day's Low
$0.25
Volume
50,432
Avg. Vol
514,948
52-wk High
$1.82
52-wk Low
$0.12

Latest Key Developments (Source: Significant Developments)

Akers Biosciences Announces Lifting Of Temporary Suspension Of Trading On The London Stock Exchange
Thursday, 26 Jul 2018 

July 26 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES ANNOUNCES LIFTING OF TEMPORARY SUSPENSION OF TRADING ON THE LONDON STOCK EXCHANGE.AKERS BIOSCIENCES - SUSPENSION OF TRADING IN CO'S SHARES ON LONDON STOCK EXCHANGE'S AIM MARKET LIFTED WITH EFFECT FROM 26 JULY AT 7.30 A.M. UK TIME.  Full Article

Akers Biosciences Withdraws FDA 510(K) Submission For PIFA
Tuesday, 29 May 2018 

May 29 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES WITHDRAWS FDA 510(K) SUBMISSION FOR PIFA CHLAMYDIA RAPID ASSAY PENDING FURTHER EVALUATION.AKERS BIOSCIENCES- DECIDED TO WITHDRAW INITIAL 510(K) APPLICATION FOR PIFA CHLAMYDIA TO RE-EVALUATE OPTIONS DUE TO THE PRODUCT DEVELOPMENT OPPORTUNITY.  Full Article

Akers Biosciences Files Non Timely 10-Q - SEC Filing
Wednesday, 16 May 2018 

May 16 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING.  Full Article

Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES - BOARD TERMINATED RAYMOND AKERS FROM POSITION AS EXECUTIVE CHAIRMAN OF BOARD, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY.AKERS BIOSCIENCES INC - RAYMOND AKERS CONTINUES AS A MEMBER OF BOARD - SEC FILING.AKERS BIOSCIENCES INC - APPOINTED RICHARD CARLYLE TARBOX III AS INTERIM NON-EXECUTIVE CHAIRMAN.  Full Article

Akers Biosciences Signs Distribution Agreement With Diagnostica Stago
Monday, 26 Mar 2018 

March 26 (Reuters) - Akers Biosciences Inc ::AKERS BIOSCIENCES SIGNS US DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO.AKERS BIOSCIENCES - ENTERED 3-YEAR NATIONAL DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO INC.AKERS BIOSCIENCES - AGREEMENT FOR SALE OF CO'S RAPID TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA ACROSS US.  Full Article

Bigger Capital Fund Reports An 8 Pct Passive Stake In Akers Biosciences
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Biosciences Inc ::BIGGER CAPITAL FUND LP REPORTS AN 8 PCT PASSIVE STAKE IN AKERS AS OF DEC 21, 2017 - SEC FILING.  Full Article

Alpha Capital Anstalt Reports 9.9 Pct Passive Stake In Akers Biosciences
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Alpha Capital Anstalt::ALPHA CAPITAL ANSTALT REPORTS 9.9 PERCENT PASSIVE STAKE IN AKERS BIOSCIENCES INC AS ON DECEMBER 21 - SEC FILING.  Full Article

Akers Biosciences says Q3 revenue rose 10 pct to $675,800
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akers Biosciences Inc -:Akers Biosciences announces Q3 2017 earnings.Q3 revenue rose 10 percent to $675,800.Akers Biosciences Inc - ‍Q3 gross margin reduced to 52%​.  Full Article

BRIEF-Akers Biosciences Files Non Timely 10-Q - SEC Filing

* AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING Source text: (https://bit.ly/2k6a2jr) Further company coverage: